Future Market Insights
Bronchopulmonary dysplasia is a chronic respiratory disease, which is most commonly occurs in premature infants and who received supplemental oxygen or mechanical ventilation. It is also called as respiratory distress syndrome. In addition, bronchopulmonary dysplasia can also occur in infants who experience abnormal lung development or had pre-birth antenatal infection. Most of the infants recover from bronchopulmonary dysplasia, however, some of those have continued lung function and structure abnormalities during adolescence and adulthood. This condition can cause serious complications during infancy and might requires hospitalization and intensive medical care, during the first 2 years after birth. The signs and symptoms for BPS includes shallow, rapid breathing, chronic cough, shortness of breath, flaring of nostrils while breathing, and discoloration of skin owing to low blood oxygen levels. Many cases of BPD are associated with excess oxygen levels and mechanical ventilation. The disease can cause from other conditions such as antenatal infection, maternal complications, preeclampsia, and inflammation of the fetal membranes, that affects the development of the lungs.
Bronchopulmonary Dysplasia Treatment Market: Drivers and Restraints
According to the Airway estimates, in Europe and the U.S. up to 160,000 infants are at highest risk for the development of BPD collectively, each year. Similarly, With 73.6 million live births in Asia and a preterm rate <32 weeks of approximately 2.2%. Government initiatives, favorable reimbursement policies, increasing prevalence of bronchopulmonary dysplasia, and raise in cases of premature births leading to bronchopulmonary dysplasia are boosting the growth of bronchopulmonary dysplasia treatment market over the forecast period. Growing research and development activities by pharmaceutical companies to develop innovative treatment option for bronchopulmonary dysplasia would boost the market in near future.
Bronchopulmonary Dysplasia Treatment Market: Segmentation
The global bronchopulmonary dysplasia treatment market is classified on the basis of drug class, therapy type end user, and geography.
Based on drug type, the global bronchopulmonary dysplasia treatment market is segmented into the following:
Based on therapy type, the global bronchopulmonary dysplasia treatment market is segmented into the following:
Nitric Oxide Therapy
Protein replacement therapy
Stem Cell Therapy
Based on end user, the global bronchopulmonary dysplasia treatment market is segmented into the following:
Critical Care Centers
Bronchopulmonary Dysplasia Treatment Market: Overview
Companies are focusing on the development of novel treatment option for bronchopulmonary dysplasia for the faster action and quick relief than the conventional dosage forms. For instance, Airway Therapeutics, LLC developed AT-100, a recombinant form of human surfactant protein, for maintaining healthy lung function in infants with bronchopulmonary dysplasia. On the other hand, research are developing stem cell therapy for novel therapeutic modality for attenuating BPD severity. Moreover, the first phase I clinical trial of stem cell transplantation for bronchopulmonary dysplasia is successfully conducted by proving its safety and feasibility in the preterm infants.
Bronchopulmonary Dysplasia Treatment Market: Regional Overview
Region wise, the global bronchopulmonary dysplasia treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and Middle East and Africa. North America expected to dominate the global market for bronchopulmonary dysplasia treatment due to favorable government policies, increased in awareness about the bronchopulmonary dysplasia, and high treatment rate are expected to drive the growth of the market over the forecast period. Large patient pool in the Asia –Pacific excluding Japan market are expected to boost the growth of the bronchopulmonary dysplasia treatment market growth in APEJ region over the forecast period.
Bronchopulmonary Dysplasia Treatment Market: Key Players
Some of the players in global bronchopulmonary dysplasia treatment market include Airway Therapeutics LLC, Chiesi Farmaceutici SpA, Insmed Incorporated, MediPost Co., Ltd., Meridigen Biotech Co., Ltd, Syntrix Biosystems, Inc., Therabron Therapeutics, In,
The report covers exhaustive analysis on:
Supply & Demand
Competition & Companies involved
Regional analysis includes
North America (U.S., Canada)
Latin America (Mexico, Brazil)
Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
Eastern Europe (Russia, Poland, Rest Of Eastern Europe)
Asia Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
Middle East and Africa (GCC, S. Africa, N. Africa, Rest Of MEA)
MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.
The report provides the following information:
The main aim of the report is to:
MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.